These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 25251308)

  • 1. Prescription drug monitoring programs and buprenorphine maintenance: clinical considerations.
    Hoefer M; Petrakis I
    Am J Addict; 2014; 23(6):616-7. PubMed ID: 25251308
    [No Abstract]   [Full Text] [Related]  

  • 2. Time to include buprenorphine-naloxone combination in the WHO Model List of Essential Medicines.
    Balhara YP
    J Opioid Manag; 2013; 9(4):237. PubMed ID: 24380101
    [No Abstract]   [Full Text] [Related]  

  • 3. Buprenorphine diversion and misuse in outpatient practice.
    Lofwall MR; Martin J; Tierney M; Fatséas M; Auriacombe M; Lintzeris N
    J Addict Med; 2014; 8(5):327-32. PubMed ID: 25221985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of adolescent opioid dependence: no quick fix.
    Fiellin DA
    JAMA; 2008 Nov; 300(17):2057-9. PubMed ID: 18984896
    [No Abstract]   [Full Text] [Related]  

  • 5. Hope in Fort Hope: First Nations community is winning the battle against prescription drug abuse.
    Uddin F
    Can Fam Physician; 2013 Apr; 59(4):391-3. PubMed ID: 23585610
    [No Abstract]   [Full Text] [Related]  

  • 6. Office-based practice and opioid-use disorders.
    Clark HW
    N Engl J Med; 2003 Sep; 349(10):928-30. PubMed ID: 12954740
    [No Abstract]   [Full Text] [Related]  

  • 7. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
    Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
    Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, effectiveness and tolerance of buprenorphine-naloxone in the treatment of opioid dependence: results from a nationwide non-interventional study in routine care.
    Apelt SM; Scherbaum N; Gölz J; Backmund M; Soyka M
    Pharmacopsychiatry; 2013 May; 46(3):94-107. PubMed ID: 23293011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of buprenorphine for substance-abuse treatment by HIV care providers.
    Friedland G; Vlahov D
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S1-2. PubMed ID: 21317588
    [No Abstract]   [Full Text] [Related]  

  • 10. In brief: Buprenorphine/naloxone (Zubsolv) for opioid dependence.
    Med Lett Drugs Ther; 2013 Oct; 55(1427):83. PubMed ID: 24129113
    [No Abstract]   [Full Text] [Related]  

  • 11. Accessing opiate dependence treatment medications: buprenorphine products in an office-based setting.
    Leshner AI
    Drug Alcohol Depend; 2003 May; 70(2 Suppl):S103-4. PubMed ID: 12738354
    [No Abstract]   [Full Text] [Related]  

  • 12. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.
    Mammen K; Bell J
    Expert Opin Pharmacother; 2009 Oct; 10(15):2537-44. PubMed ID: 19708849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tramadol dependence: treatment with buprenorphine/naloxone.
    Ritvo JI; Koonce R; Thurstone CC; Causey HL
    Am J Addict; 2007; 16(1):67-8. PubMed ID: 17364425
    [No Abstract]   [Full Text] [Related]  

  • 14. Medication helps make therapy work for teens addicted to prescription opioids.
    Kuehn BM
    JAMA; 2010 Jun; 303(23):2343-5. PubMed ID: 20551400
    [No Abstract]   [Full Text] [Related]  

  • 15. Buprenorphine maintenance: a new treatment for opioid dependence.
    Collins GB; McAllister MS
    Cleve Clin J Med; 2007 Jul; 74(7):514-20. PubMed ID: 17682629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population.
    McDermott KA; Griffin ML; Connery HS; Hilario EY; Fiellin DA; Fitzmaurice GM; Weiss RD
    J Clin Psychiatry; 2015 Feb; 76(2):189-94. PubMed ID: 25562462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loperamide Addiction: Atypical Opioid Use Disorder Treated With Buprenorphine/Naloxone.
    Varghese SP; Kumari P; Wijegunaratne H; Yovankin T; Garlapati V; Koola MM
    Prim Care Companion CNS Disord; 2019 Jul; 21(4):. PubMed ID: 31274259
    [No Abstract]   [Full Text] [Related]  

  • 18. The Need to Rule Out Intranasal Self-administration of Buprenorphine-Naloxone Combinations Before Prescribing Buprenorphine Without Naloxone.
    Mendelson J
    J Addict Med; 2023 Jan-Feb 01; 17(1):119. PubMed ID: 35914117
    [No Abstract]   [Full Text] [Related]  

  • 19. Use and misuse of opioid replacement therapies: a Queensland study.
    Smirnov A; Kemp R
    Subst Use Misuse; 2012 Jan; 47(1):78-85. PubMed ID: 22216993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of the effect of buprenorphine/naloxone with gabapentin or quetiapine.
    Reeves RR; Ladner ME
    Am J Psychiatry; 2014 Jun; 171(6):691. PubMed ID: 24880512
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.